April 11th 2025
ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.
HIV Patients Lack Adequate Control of CVD Risk Factors
September 25th 2014Now that HIV infection is largely a chronic disease, cardiovascular disease has become a leading cause of death in this patient group. Here: a look at just how common LDL-C dyslipidemia, hypertension, and coronary heart disease really are.